.

Researchers advocating taking part in research

Current COVID-19 studies open at Barts Health

Clinical Trials of Investigational Medicinal Products (CTIMPS)

1) ACCORD-2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients

(URGENT PUBLIC HEALTH STUDY)

Specialty: Infection

Summary: The ACCORD 2 study aims to test whether medicines which we think may work against SARS-CoV-2 might be able to help people with COVID-19. To do this, several treatments will be tested, one at a time, in people with COVID-19 that have been hospitalised. Some treatments act directly against the virus when it gets into the body. These types of treatments are called anti-virals. They work by stopping the virus from making extra copies of itself. This may help stop the spread of the infection, both within the body and to other people. Other treatments help the body’s immune system (natural defence against viral infections) to work better. These types of treatments are called immunomodulatory drugs. As each existing treatment is tested in people with COVID-19, a group of doctors and researchers will look at the results to see whether it works and how safe it is. The treatment period will last about 15 days and you will be randomly assigned (by chance) to receive the study drug with standard-of-care or standard-of-care only. You and the study doctor will know if you receive the study drug or not. All participants taking part in this study will continue to receive the currently accepted standard-of-care for COVID-19.

Sponsor: University Hospital Southampton NHS Foundation Trust

Barts Health Research Manager: Anne Zak 

 

2) RECOVERY trial

(URGENT PUBLIC HEALTH STUDY)

IRAS category/study type: CTIMP (Clinical Trial of an Investigational Medicinal Product)

Specialty: Infection 

Summary: This is a drug trial with adaptive design that aims to test how effective various medicines are at treating COVID-19. In order to test the medicines, the patient will be randomly allocated to one out of five possible treatments. As the study goes along, it may change, treatments which don’t work will be removed, and others can be added. The patient will be randomly allocated one of these treatments to compare their effects in the ratio of 1:1:1:1:2 so twice as many patients get active drugs as get placebo. Neither the patient nor the researcher choose which treatment the patient receives.

Sponsor: University of Oxford 

Barts Health Research Manager: David Lieberman

For more information: Email the RECOVERY study team or visit the RECOVERY study website

 

3) REMAP-CAP

(URGENT PUBLIC HEALTH STUDY)

Specialty: Critical Care

Summary: This clinical trial is for those patients who have been diagnosed with Community Acquired Pneumonia (CAP). There are a number of different antibiotics that are widely used for patients with CAP which are safe and effective, however it is not currently known which ones are best in the treatment of COVID-19. This trial looks at a number of different treatments with the aim of determining the best package of treatments for patients. The treatments being investigated in this study are the same as the treatments the patient would receive in normal clinical care.The only difference is that the study will randomly determine which treatment is received, instead of the doctor.

Sponsor: Imperial

Barts Health Research Manager: Ruzena Uddin 

 

 

Data studies

1) The PRIEST study

(URGENT PUBLIC HEALTH STUDY)

Specialty: Emergency care

Summary: We aim to optimise the triage of people using the emergency care system (111 and 99calls, ambulance conveyance, or hospital emergency department) with suspected respiratory infections during a pandemic and identify the most accurate triage method for predicting severe illness among patients attending the emergency department with suspected respiratory infection.

Sponsor: Sheffield Teaching Hospital

Barts Health Research Manager: Imogen Skene

 

2) A Multi-center, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults with Severe COVID-19

Specialty: Infection

Summary: This is a multi-center, multi-country retrospective cohort study. Up to 2000 severe COVID-19 cases across up to 50 participating study sites who meet all eligibility criteria will be included in the analysis. Deidentified data will be extracted from electronic medical record (EMR) databases, clinical registries, case series or additional sources from participating sites and countries, and then entered into a structured e-CRF system (or transferred electronically if feasible), then pooled into one database with standard data format. This real-world standard of care (SOC) cohort can be used to assess efficacy comparisons to potential future treatments. In addition, each site/country will be surveyed to determine the local standard of care therapy for COVID-19 infection.

Sponsor: Gilead

Barts Health Research Manager: James Hand

 

3) ETHICAL: Ethnic Disparities In COVID-19 Admissions in east London

Specialty: Infection/Intensive Care Unit

Summary: An observational cohort study of treatment and outcomes in Black, Asian and Minority Ethnic (BAME) and non-BAME patients with a confirmed diagnosis of COVID-19 (positive SARS-CoV-2 swab) admitted to Barts Health.

Sponsor: Barts Health NHS Trust/Queen Mary University London

 

4) Generating Evidence to Fight COVID-19: the COVIDENCE study

Specialty: Respiratory/Generic

Summary:  The COVIDENCE Research Study has been developed in response to the outbreak of coronavirus (COVID-19). People aged 16 and over will be asked to provide some baseline information about their lifestyle and health using an online questionnaire. They will then be contacted once a month to check if they have developed symptoms of coronavirus infection or if they have attended a hospital for treatment. No individual will be recognisable from the data and all information will be strictly confidential. The study has four goals: 1. To learn more about risk factors for coronavirus infection in UK adults 2. To find out how quickly people recover from coronavirus infection, and whether there are any long-term complications of this illness 3. To evaluate the impact of coronavirus infection on the physical and mental well-being of the UK population 4. To establish a database of people who may be interested in taking part in future clinical trials, and to invite selected people to participate in those trials.

Sponsor: Queen Mary University London

For more information email COVIDENCE at Queen Mary University of London

Basic science studies involving procedures with human participants

1) GenOMICC Study

(URGENT PUBLIC HEALTH STUDY)

Specialty: Infection

Summary: The GenOMICC study hopes to identify the specific genes that cause some people to be susceptible to COVID-19 as well as the genes that may help them survive infection. By taking a small blood sample from COVID-19 patients, the study aims to identify specific treatments that may, in future, help people to survive severe illness. To do this, the study will compare the whole sequence of the DNA and cells from COVID-19 patients with DNA already obtained from healthy people in studies such as UK Biobank and the 100,000 Genomes Project for rare disease.

Sponsor: University of Edinburgh and NHS Lothian

Barts Health Research Manager: Suzanne Wood

For more information contact Suzanne Wood  or Anne Zak by email or phone: 07907 930 321

 

2) ISARIC: Clinical Characterisation Protocol for Severe Emerging Infection

(URGENT PUBLIC HEALTH STUDY)

Specialty: Infection 

Summary: This research study will gather important information about COVID-19 to find better ways to manage and treat it in the future. The study will take tissue samples from the patient and collect information from medical notes. The patient will be asked to give: a blood sample; a swab or suction sample from the mouth, nose and throat; and other samples e.g. mucus, urine. These samples will be taken three times over the course of the hospital stay and a final set of samples a month after release from hospital.

Sponsor: University of Oxford

For more information email Helena Walsh 

 

3) COVID-19: Healthcare worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2

Specialty: Cardiovascular

Summary: This study aims to understand the 2019 coronavirus outbreak better and the body’s response to it, which will be important to understanding any subsequent waves of COVID, vaccine development and theraputics. To do this, there is a need to understand the NHS workforce so we are recruiting healthy care workers (nurses, doctors, health care assistants, pharmacists, ward clerks etc) across Barts Health hospitals, in Accident and Emergency, Adult Medical Admissions Unit, Medical and Surgical Wards and Intensive Care Units. The team will collect swabs, and do blood sampling at baseline, and weekly whilst the participant is well and attending work, with acute sampling (if hospitalised, via ISARIC) and samples post illness, during the recovery period. This will hopefully increase the understanding of factors behind population immunity and why some individuals are protected against new viruses. Participants will be free to withdraw from the study at any point. ‚Äč

Sponsor: University College London Hospitals NHS Foundation Trust

Barts Health Research Manager: Maudrian Burton

 

4) Patient recovery from heart surgery during the Covid-19 pandemic

Specialty: Cardiovascular

Summary: During this pandemic, a lot of focus is on the pandemic itself and in critical care. However, during this time people still need urgent or emergency heart surgery. There is very little information that describes heart surgery during a pandemic, including in those who have had their surgery postponed or delayed, or have a different treatment because their surgery was postponed or delayed, and the effect it might have on patients recovering from the operation. We would like to explore this and follow your recovery over the 12 months – one week after you are discharge from hospital (if you agree to take part in the study while you are in hospital), and then six weeks, six months and one year after surgery. This will help us to understand what, if any, the impact of having heart surgery during the pandemic has on patients. The study will use questionnaires and telephone interviews.

Sponsor: Barts Health NHS Trust